Vrajesh Parekh

Vrajesh Parekh's work experience begins in 1997 when they started as a Ph.D. student at the National Center for Cell Science. Their research topic focused on inducing tolerance in CD8+ T cells. From 2003 to 2012, they worked as a post-doctoral research fellow at Vanderbilt University Medical Center, where they conducted research on the response of invariant natural killer T (iNKT) cells to glycolipids and their ability to prevent experimental autoimmune encephalomyelitis (EAE) in mice. Vrajesh then moved on to become a research assistant professor at Vanderbilt, where they played a leading role in identifying scientific problems, framing hypotheses, designing experiments, and mentoring fellow scientists. In 2016, Parekh joined Pfizer as a senior scientist before transitioning to Vividion Therapeutics, Inc. in 2018. At Vividion, they held the position of senior scientist before being promoted to principal scientist in February 2022. The exact end dates for several roles are not provided.

Vrajesh Parekh's education history includes a Ph.D. in Immunology from Devi Ahilya Vishwavidyalaya from 1997 to 2003. Prior to that, they obtained a Master of Science (MSc) in Biochemistry from The Maharaja Sayajirao University of Baroda from 1994 to 1996. Their undergraduate degree, a Bachelor of Science (B.Sc.), was also earned at The Maharaja Sayajirao University of Baroda from 1991 to 1994, with a focus in Zoology, Chemistry, and Botany. Vrajesh's education history also mentions enrollment at the National Center for Cell Science, Pune and GSFC, Baroda, but no specific degree or field of study is provided for these institutions.